Drug transport proteins in the liver

Advanced Drug Delivery Reviews

Volumn 55, Issue 1, 2003, Pages 107-124

  Faber, Klaas Nico ^a   Müller, Michael ^b   Jansen, Peter L M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

ATP binding cassette transporters; Drug efflux pumps; Multidrug resistance proteins; Nuclear hormone receptors; Organic anion transporting proteins; Organic cation transporting protein; P Glycoproteins; Prostaglandin transporter; Solute carriers

Indexed keywords

BIOLOGICAL MEMBRANES; BIOLOGICAL ORGANS; DISEASES; HYDROLYSIS; METABOLISM; PROTEINS; SALTS;

TRANSMEMBRANE TRANSPORTERS;

DRUG INTERACTIONS;

ABC TRANSPORTER; BILE ACID; BILE SALT; BUMETANIDE; CARRIER PROTEIN; CHLORAMBUCIL; CISPLATIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYTOKINE; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; HORMONE RECEPTOR; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER POLYPEPTIDE 8; ORGANIC ANION TRANSPORTER POLYPEPTIDE A; ORGANIC ANION TRANSPORTER POLYPEPTIDE B; ORGANIC ANION TRANSPORTER POLYPEPTIDE C; ORGANIC CATION TRANSPORTER; PRASTERONE; PROSTAGLANDIN; PROSTAGLANDIN TRANSPORTER; SODIUM DEPENDENT TAUROCHOLATE COTRANSPORTING PROTEIN; STEROID; THYROID HORMONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VERAPAMIL;

BASOLATERAL MEMBRANE; BILE; CHOLESTASIS; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSPORT; ENZYME SPECIFICITY; GENETIC CODE; GENETIC POLYMORPHISM; HUMAN; HYDROLYSIS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW;

EID: 0037457798     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00173-4     Document Type: Article

References (177)

1. Kullak-Ublick G.A., Jung D., Ismair M.G., Meier P.J. Uptake of drugs into the liver. Matern S., Boyer J.L., Keppler D., Meier-Abt P.J. Hepatobiliary Transport: From Bench To Bedside. 2001;37-43 Kluwer Academic Publishers, Dordrecht, Boston, London.
2. Hagenbuch B., Meier P.J. Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. Semin. Liver Dis. 16:(2):1996;129-136.
3. Schroeder A., Eckhardt U., Stieger B., Tynes R., Schteingart C.D., Hofmann A.F., et al. Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am. J. Physiol. 274:(2 Pt 1):1998;G370-G375.
4. Kouzuki H., Suzuki H., Stieger B., Meier P.J., Sugiyama Y. Characterization of the transport properties of organic anion transporting polypeptide 1 (oatp1) and Na(+)/taurocholate cotransporting polypeptide (Ntcp): comparative studies on the inhibitory effect of their possible substrates in hepatocytes and cDNA-transfected COS-7 cells. J. Pharmacol. Exp. Ther. 292:(2):2000;505-511.
5. Friesema E.C., Docter R., Moerings E.P., Stieger B., Hagenbuch B., Meier P.J., et al. Identification of thyroid hormone transporters. Biochem. Biophys. Res. Commun. 254:(2):1999;497-501.
6. Akhteruzzaman S., Kato Y., Kouzuki H., Suzuki H., Hisaka A., Stieger B., et al. Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. J. Pharmacol. Exp. Ther. 290:(3):1999;1107-1115.
7. Kullak-Ublick G.A., Glasa J., Boker C., Oswald M., Grutzner U., Hagenbuch B., et al. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology. 113:(4):1997;1295-1305.
8. Kramer W., Wess G., Schubert G., Bickel M., Girbig F., Gutjahr U., et al. Liver-specific drug targeting by coupling to bile acids. J. Biol. Chem. 267:(26):1992;18598-18604.
9. Briz O., Serrano M.A., Rebollo N., Hagenbuch B., Meier P.J., Koepsell H., et al. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol. Pharmacol. 61:(4):2002;853-860.
10. Larena M.G., Martinez-Diez M.C., Monte M.J., Dominguez M.F., Pascual M.J., Marin J.J. Liver organotropism and biotransformation of a novel platinum-ursodeoxycholate derivative, Bamet-UD2, with enhanced antitumour activity. J. Drug Target. 9:(3):2001;185-200.
11. Dominguez M.F., Macias R.I., Izco-Basurko I., de La F.A., Pascual M.J., Criado J.M., et al. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J. Pharmacol. Exp. Ther. 297:(3):2001;1106-1112.
12. Fiorucci S., Antonelli E., Morelli O., Mencarelli A., Casini A., Mello T., et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc. Natl. Acad. Sci. USA. 98:(15):2001;8897-8902.
13. Fiorucci S., Mencarelli A., Palazzetti B., del Soldato P., Morelli A., Ignarro L.J. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc. Natl. Acad. Sci. USA. 98:(5):2001;2652-2657.
14. Reichel C., Gao B., Van Montfoort J., Cattori V., Rahner C., Hagenbuch B., et al. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology. 117:(3):1999;688-695.
15. Tamai I., Nezu J., Uchino H., Sai Y., Oku A., Shimane M., et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273:(1):2000;251-260.
16. Konig J., Cui Y., Nies A.T., Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 275:(30):2000;23161-23168.
17. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 120:(2):2001;525-533.
18. Eckhardt U., Schroeder A., Stieger B., Hochli M., Landmann L., Tynes R., et al. Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am. J. Physiol. 276:(4 Pt 1):1999;G1037-G1042.
19. van Montfoort J.E., Hagenbuch B., Fattinger K.E., Muller M., Groothuis G.M., Meijer D.K., et al. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J. Pharmacol. Exp. Ther. 291:(1):1999;147-152.
20. Ismair M.G., Stieger B., Cattori V., Hagenbuch B., Fried M., Meier P.J., et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides oatp4 and oatp8 of rat and human liver. Gastroenterology. 121:(5):2001;1185-1190.
21. Cui Y., Konig J., Leier I., Buchholz U., Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276:(13):2001;9626-9630.
22. Cattori V., van Montfoort J.E., Stieger B., Landmann L., Meijer D.K., Winterhalter K.H., et al. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 443:(2):2001;188-195.
23. Cattori V., Hagenbuch B., Hagenbuch N., Stieger B., Ha R., Winterhalter K.E., et al. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Lett. 474:(2-3):2000;242-245.
24. Abe T., Kakyo M., Sakagami H., Tokui T., Nishio T., Tanemoto M., et al. Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J. Biol. Chem. 273:(35):1998;22395-22401.
25. Walters H.C., Craddock A.L., Fusegawa H., Willingham M.C., Dawson P.A. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am. J. Physiol. Gastrointest. Liver Physiol. 279:(6):2000;G1188-G1200.
26. Suzuki H., Sugiyama Y. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. Semin. Liver Dis. 20:(3):2000;251-263.
27. Dubuisson C., Cresteil D., Desrochers M., Decimo D., Hadchouel M., Jacquemin E. Ontogenic expression of the Na(+)-independent organic anion transporting polypeptide (oatp) in rat liver and kidney. J. Hepatol. 25:(6):1996;932-940.
28. Hagenbuch N., Reichel C., Stieger B., Cattori V., Fattinger K.E., Landmann L., et al. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J. Hepatol. 34:(6):2001;881-887.
29. Li L., Meier P.J., Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol. Pharmacol. 58:(2):2000;335-340.
30. Li L., Lee T.K., Meier P.J., Ballatori N. Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J. Biol. Chem. 273:(26):1998;16184-16191.
31. Satlin L.M., Amin V., Wolkoff A.W. Organic anion transporting polypeptide mediates organic anion/HCO3-exchange. J. Biol. Chem. 272:(42):1997;26340-26345.
32. Sekine T., Cha S.H., Endou H. The multispecific organic anion transporter (OAT) family. Pflugers Arch. 440:(3):2000;337-350.
33. Sekine T., Cha S.H., Tsuda M., Apiwattanakul N., Nakajima N., Kanai Y., et al. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 429:(2):1998;179-182.
34. Sweet D.H., Miller D.S., Pritchard J.B., Fujiwara Y., Beier D.R., Nigam S.K. Impaired Organic Anion Transport in Kidney and Choroid Plexus of Organic Anion Transporter 3 (Oat3 (Slc22a8)) Knockout Mice. J. Biol. Chem. 277:(30):2002;26934-26943.
35. Sekine T., Watanabe N., Hosoyamada M., Kanai Y., Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 272:(30):1997;18526-18529.
36. Lu R., Kanai N., Bao Y., Schuster V.L. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J. Clin. Invest. 98:(5):1996;1142-1149.
37. Kanai N., Lu R., Satriano J.A., Bao Y., Wolkoff A.W., Schuster V.L. Identification and characterization of a prostaglandin transporter. Science. 268:(5212):1995;866-869.
38. Lu R., Kanai N., Bao Y., Schuster V.L. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J. Clin. Invest. 98:(5):1996;1142-1149.
39. Kanai N., Lu R., Satriano J.A., Bao Y., Wolkoff A.W., Schuster V.L. Identification and characterization of a prostaglandin transporter. Science. 268:(5212):1995;866-869.
40. Abe T., Kakyo M., Tokui T., Nakagomi R., Nishio T., Nakai D., et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274:(24):1999;17159-17163.
41. Moseley R.H., Vashi P.G., Jarose S.M., Dickinson C.J., Permoad P.A. Thiamine transport by basolateral rat liver plasma membrane vesicles. Gastroenterology. 103:(3):1992;1056-1065.
42. Moseley R.H., Morrissette J., Johnson T.R. Transport of N1-methylnicotinamide by organic cation-proton exchange in rat liver membrane vesicles. Am. J. Physiol. 259:(6 Pt 1):1990;G973-G982.
43. Steen H., Merema M., Meijer D.K. A multispecific uptake system for taurocholate, cardiac glycosides and cationic drugs in the liver. Biochem. Pharmacol. 44:(12):1992;2323-2331.
44. Steen H., Oosting R., Meijer D.K. Mechanisms for the uptake of cationic drugs by the liver: a study with tributylmethylammonium (TBuMA). J. Pharmacol. Exp. Ther. 258:(2):1991;537-543.
45. Nagel G., Volk C., Friedrich T., Ulzheimer J.C., Bamberg E., Koepsell H. A reevaluation of substrate specificity of the rat cation transporter rOCT1. J. Biol. Chem. 272:(51):1997;31953-31956.
46. Martel F., Vetter T., Russ H., Grundemann D., Azevedo I., Koepsell H., et al. Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedeberg's Arch. Pharmacol. 354:(3):1996;320-326.
47. Grundemann D., Gorboulev V., Gambaryan S., Veyhl M., Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 372:(6506):1994;549-552.
48. Zhang L., Dresser M.J., Gray A.T., Yost S.C., Terashita S., Giacomini K.M. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51:(6):1997;913-921.
49. Gorboulev V., Ulzheimer J.C., Akhoundova A., Ulzheimer-Teuber I., Karbach U., Quester S., et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16:(7):1997;871-881.
50. Busch A.E., Quester S., Ulzheimer J.C., Waldegger S., Gorboulev V., Arndt P., et al. Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J. Biol. Chem. 271:(51):1996;32599-32604.
51. Dresser M.J., Gray A.T., Giacomini K.M. Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J. Pharmacol. Exp. Ther. 292:(3):2000;1146-1152.
52. Mehrens T., Lelleck S., Cetinkaya I., Knollmann M., Hohage H., Gorboulev V., et al. The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation. J. Am. Soc. Nephrol. 11:(7):2000;1216-1224.
53. Jonker J.W., Wagenaar E., Mol C.A., Buitelaar M., Koepsell H., Smit J.W., et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol. Cell Biol. 21:(16):2001;5471-5477.
54. van Montfoort J.E., Müller M., Groothuis G.M., Meijer D.K., Koepsell H., Meier P.J. Comparison of 'type I' and 'type II' organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J. Pharmacol. Exp. Ther. 298:(1):2001;110-115.
55. Hirom P.C., Millburn P., Smith R.L. Bile and urine as complementary pathways for the excretion of foreign organic compounds. Xenobiotica. 6:(1):1976;55-64.
56. Hirom P.C., Millburn P., Smith R.L., Williams R.T. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem. J. 129:(5):1972;1071-1077.
57. Hirom P.C., Millburn P., Smith R.L., Williams R.T. Molecular weight and chemical structure as factors in the biliary excretion of sulphonamides in the rat. Xenobiotica. 2:(3):1972;205-214.
58. Xiong H., Turner K.C., Ward E.S., Jansen P.L., Brouwer K.L. Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J. Pharmacol. Exp. Ther. 295:(2):2000;512-518.
59. Sathirakul K., Suzuki H., Yamada T., Hanano M., Sugiyama Y. Multiple transport systems for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther. 268:(1):1994;65-73.
60. Sathirakul K., Suzuki H., Yasuda K., Hanano M., Tagaya O., Horie T., et al. Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. J. Pharmacol. Exp. Ther. 265:(3):1993;1301-1312.
61. Sasabe H., Kato Y., Terasaki T., Tsuji A., Sugiyama Y. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. Biopharm. Drug Dispos. 20:(3):1999;151-158.
62. Abadia A.R., De Francesco L., Guaitani A. Disposition of ciprofloxacin in the isolated perfused rat liver. Drug Metab. Dispos. 23:(2):1995;197-200.
63. Konig J., Nies A.T., Cui Y., Leier I., Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta. 1461:(2):1999;377-394.
64. Roelofsen H., Hooiveld G.J., Koning H., Havinga R., Jansen P.L., Müller M. Glutathione S-conjugate transport in hepatocytes entering the cell cycle is preserved by a switch in expression from the apical MRP2 to the basolateral MRP1 transporting protein. J. Cell. Sci. 112:(Pt 9):1999;1395-1404.
65. Vos T.A., Hooiveld G.J., Koning H., Childs S., Meijer D.K., Moshage H., et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology. 28:(6):1998;1637-1644.
66. Keppler D., Kamisako T., Leier I., Cui Y., Nies A.T., Tsujii H., et al. Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family. Adv. Enzyme Regul. 40:2000;339-349.
67. Konig J., Rost D., Cui Y., Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology. 29:(4):1999;1156-1163.
68. Hirohashi T., Suzuki H., Takikawa H., Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J. Biol. Chem. 275:(4):2000;2905-2910.
69. Keppler D., Leier I., Jedlitschky G., Konig J. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem. Biol. Interact. 111-112:1998;153-161.
70. Pei Q.L., Kobayashi Y., Tanaka Y., Taguchi Y., Higuchi K., Kaito M., et al. Increased expression of multidrug resistance-associated protein 1 (mrp1) in hepatocyte basolateral membrane and renal tubular epithelia after bile duct ligation in rats. Hepatol. Res. 22:(1):2002;58-64.
71. Vos T.A., Ros J.E., Havinga R., Moshage H., Kuipers F., Jansen P.L., et al. Regulation of hepatic transport systems involved in bile secretion during liver regeneration in rats. Hepatology. 29:(6):1999;1833-1839.
72. Kiuchi Y., Suzuki H., Hirohashi T., Tyson C.A., Sugiyama Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett. 433:(1-2):1998;149-152.
73. Ogawa K., Suzuki H., Hirohashi T., Ishikawa T., Meier P.J., Hirose K., et al. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 278:(3):2000;G438-G446.
74. Ogawa K., Suzuki H., Hirohashi T., Ishikawa T., Meier P.J., Hirose K., et al. Characterization of inducible nature of MRP3 in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 278:(3):2000;G438-G446.
75. Cherrington N.J., Hartley D.P., Li N., Johnson D.R., Klaassen C.D. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J. Pharmacol. Exp. Ther. 300:(1):2002;97-104.
76. Soroka C.J., Lee J.M., Azzaroli F., Boyer J.L. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. Hepatology. 33:(4):2001;783-791.
77. Donner M.G., Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology. 34:(2):2001;351-359.
78. Madon J., Hagenbuch B., Landmann L., Meier P.J., Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. Mol. Pharmacol. 57:(3):2000;634-641.
79. Jansen P.L.M., Peters W.H., Lamers W.H. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology. 5:(4):1985;573-579.
80. Jansen P.L.M., Groothuis G.M., Peters W.H., Meijer D.F. Selective hepatobiliary transport defect for organic anions and neutral steroids in mutant rats with hereditary-conjugated hyperbilirubinemia. Hepatology. 7:(1):1987;71-76.
81. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:(4):1994;491-502.
82. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxine, and cyclosporin A. J. Clin. Invest. 96:(4):1995;1698-1705.
83. Grant C.E., Valdimarsson G., Hipfner D.R., Almquist K.C., Cole S.P., Deeley R.G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54:(2):1994;357-361.
84. Müller M., Meijer C., Zaman G.J., Borst P., Scheper R.J., Mulder N.H., et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. USA. 91:(26):1994;13033-13037.
85. Yang X., Uziely B., Groshen S., Lukas J., Israel V., Russell C., et al. MDR1 gene expression in primary and advanced breast cancer. Lab. Invest. 79:(3):1999;271-280.
86. van der Kolk D.M., de Vries E.G., Noordhoek L., van den B.E., van der Pol M.A., Müller M., et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia. 15:(10):2001;1544-1553.
87. Sonneveld P., Wiemer E. Inhibitors of multidrug resistance. Curr. Opin. Oncol. 9:(6):1997;543-548.
88. Sharom F.J., Yu X., Lu P., Liu R., Chu J.W., Szabo K., et al. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem. Pharmacol. 58:(4):1999;571-586.
89. Aran J.M., Pastan I., Gottesman M.M. Therapeutic strategies involving the multidrug resistance phenotype: the MDR1 gene as target, chemoprotectant, and selectable marker in gene therapy. Adv. Pharmacol. 46:(1-42):1999;1-42.
90. Licht T., Gottesman M.M., Pastan I. Transfer of the MDR1 (multidrug resistance) gene: protection of hematopoietic cells from cytotoxic chemotherapy, and selection of transduced cells in vivo. Cytokines Mol. Ther. 1:(1):1995;11-20.
91. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 8:(3):1997;161-170.
92. Ros J.E., Schuetz J.D., Geuken M., Streetz K., Moshage H., Kuipers F., et al. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology. 33:(6):2001;1425-1431.
93. Brady J.M., Cherrington N.J., Hartley D.P., Buist S.C., Li N., Klaassen C.D. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab. Dispos. 30:(7):2002;838-844.
94. Durr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:(6):2000;598-604.
95. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69:(3):2001;169-174.
96. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA. 97:(7):2000;3473-3478.
97. Brinkmann U., Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 1:(1):2001;59-64.
98. Ananthanarayanan M., Balasubramanian N., Makishima M., Mangelsdorf D.J., Suchy F.J. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 276:(31):2001;28857-28865.
99. Denson L.A., Sturm E., Echevarria W., Zimmerman T.L., Makishima M., Mangelsdorf D.J., et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology. 121:(1):2001;140-147.
100. Jung D., Podvinec M., Meyer U.A., Mangelsdorf D.J., Fried M., Meier P.J., et al. Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology. 122:(7):2002;1954-1966.
101. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science. 294:(5548):2001;1866-1870.
102. Zollner G., Fickert P., Silbert D., Fuchsbichler A., Stumptner C., Zatloukal K., et al. Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. Am. J. Physiol. Gastrointest. Liver Physiol. 282:(1):2002;G184-G191.
103. Wang L., Lee Y.K., Bundman D., Han Y., Thevananther S., Kim C.S., et al. Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell. 2:(6):2002;721-731.
104. Kerr T.A., Saeki S., Schneider M., Schaefer K., Berdy S., Redder T., et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev. Cell. 2:(6):2002;713-720.
105. Shih D.Q., Bussen M., Sehayek E., Ananthanarayanan M., Shneider B.L., Suchy F.J., et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat. Genet. 27:(4):2001;375-382.
106. Jung D., Hagenbuch B., Gresh L., Pontoglio M., Meier P.J., Kullak-Ublick G.A. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha. J. Biol. Chem. 276:(40):2001;37206-37214.
107. Karpen S.J., Sun A.Q., Kudish B., Hagenbuch B., Meier P.J., Ananthanarayanan M., et al. Multiple factors regulate the rat liver basolateral sodium-dependent bile acid cotransporter gene promoter. J. Biol. Chem. 271:(25):1996;15211-15221.
108. Trauner M., Arrese M., Lee H., Boyer J.L., Karpen S.J. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J. Clin. Invest. 101:(10):1998;2092-2100.
109. Denson L.A., Auld K.L., Schiek D.S., McClure M.H., Mangelsdorf D.J., Karpen S.J. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J. Biol. Chem. 275:(12):2000;8835-8843.
110. Kakyo M., Unno M., Tokui T., Nakagomi R., Nishio T., Iwasashi H., et al. Molecular characterization and functional regulation of a novel rat liver-specific organic anion transporter rlst-1. Gastroenterology. 117:(4):1999;770-775.
111. Trauner M., Arrese M., Soroka C.J., Ananthanarayanan M., Koeppel T.A., Schlosser S.F., et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology. 113:(1):1997;255-264.
112. Gartung C., Ananthanarayanan M., Rahman M.A., Schuele S., Nundy S., Soroka C.J., et al. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology. 110:(1):1996;199-209.
113. Lee J.M., Trauner M., Soroka C.J., Stieger B., Meier P.J., Boyer J.L. Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology. 118:(1):2000;163-172.
114. Kauffmann H.M., Pfannschmidt S., Zoller H., Benz A., Vorderstemann B., Webster J.I., et al. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 171:(2-3):2002;137-146.
115. Xie W., Evans R.M. Orphan nuclear receptors: the exotics of xenobiotics. J. Biol. Chem. 276:(41):2001;37739-37742.
116. Xie W., Radominska-Pandya A., Shi Y., Simon C.M., Nelson M.C., Ong E.S., et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. USA. 98:(6):2001;3375-3380.
117. Tzameli I., Moore D.D. Role reversal: new insights from new ligands for the xenobiotic receptor CAR. Trends Endocrinol. Metab. 12:(1):2001;7-10.
118. Rausch-Derra L.C., Hartley D.P., Meier P.J., Klaassen C.D. Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters, OATP1 and OATP2. Hepatology. 33:(6):2001;1469-1478.
119. Stieger B., Fattinger K., Madon J., Kullak-Ublick G.A., Meier P.J. Gastroenterology. 118:(2):2000;422-430.
120. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69:(4):2001;223-231.
121. De Vree J.M., Jacquemin E., Sturm E., Cresteil D., Bosma P.J., Aten J., et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. USA. 95:(1):1998;282-287.
122. Dixon P.H., Weerasekera N., Linton K.J., Donaldson O., Chambers J., Egginton E., et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Mol. Genet. 9:(8):2000;1209-1217.
123. Schuetz E.G., Umbenhauer D.R., Yasuda K., Brimer C., Nguyen L., Relling M.V., et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol. 57:(1):2000;188-197.
124. Blumberg B., Sabbagh W. Jr., Juguilon H., Bolado J. Jr., van Meter C.M., Ong E.S., et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 12:(20):1998;3195-3205.
125. Blumberg B., Evans R.M. Orphan nuclear receptors - new ligands and new possibilities. Genes Dev. 12:(20):1998;3149-3155.
126. Itoda M., Saito Y., Soyama A., Saeki M., Murayama N., Ishida S., et al. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab. Dispos. 30:(4):2002;363-364.
127. Conrad S., Kauffmann H.M., Ito K., Deeley R.G., Cole S.P., Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 46:(11):2001;656-663.
128. Itoda M., Saito Y., Soyama A., Saeki M., Murayama N., Ishida S., et al. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab. Dispos. 30:(4):2002;363-364.
129. Saito S., Iida A., Sekine A., Miura Y., Ogawa C., Kawauchi S., et al. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J. Hum. Genet. 47:(1):2002;38-50.
130. Conrad S., Kauffmann H.M., Ito K., Deeley R.G., Cole S.P., Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 46:(11):2001;656-663.
131. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:(2):2001;189-199.
132. Schaeffeler E., Eichelbaum M., Brinkmann U., Penger A., Asante-Poku S., Zanger U.M., et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 358:(9279):2001;383-384.
133. Cui Y., Konig J., Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter slc21a8 and the apical export pump abcc2. Mol. Pharmacol. 60:(5):2001;934-943.
134. Tamai I., Nozawa T., Koshida M., Nezu J., Sai Y., Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm. Res. 18:(9):2001;1262-1269.
135. Bossuyt X., Muller M., Meier P.J. Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J. Hepatol. 25:(5):1996;733-738.
136. Zimmerli B., Valantinas J., Meier P.J. Multispecificity of Na+-dependent taurocholate uptake in basolateral (sinusoidal) rat liver plasma membrane vesicles. J. Pharmacol. Exp. Ther. 250:(1):1989;301-308.
137. Kontaxi M., Echkardt U., Hagenbuch B., Stieger B., Meier P.J., Petzinger E. Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. J. Pharmacol. Exp. Ther. 279:(3):1996;1507-1513.
138. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13:(3):2002;595-603.
139. Chen Z.S., Lee K., Walther S., Raftogianis R.B., Kuwano M., Zeng H., et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62:(11):2002;3144-3150.
140. Morikawa A., Goto Y., Suzuki H., Hirohashi T., Sugiyama Y. Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2. Pharm. Res. 17:(5):2000;546-552.
141. Paulusma C.C., van Geer M.A., Evers R., Heijn M., Ottenhoff R., Borst P., et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem. J. 338:(Pt 2):1999;393-401.
142. Loe D.W., Deeley R.G., Cole S.P. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J. Pharmacol. Exp. Ther. 293:(2):2000;530-538.
143. Loe D.W., Deeley R.G., Cole S.P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58:(22):1998;5130-5136.
144. Loe D.W., Stewart R.K., Massey T.E., Deeley R.G., Cole S.P. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol. Pharmacol. 51:(6):1997;1034-1041.
145. Loe D.W., Deeley R.G., Cole S.P. Biology of the multidrug resistance-associated protein. MRP Eur. J. Cancer. 32A:(6):1996;945-957.
146. Evers R., Kool M., van Deemter L., Janssen H., Calafat J., Oomen L.C., et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 101:(7):1998;1310-1319.
147. Evers R., de Haas M., Sparidans R., Beijnen J., Wielinga P.R., Lankelma J., et al. Vinblastine and sulfinpyrazone export by the multidrug
148. Kool M., van der L.M., de Haas M., Scheffer G.L., De Vree J.M., Smith A.J., et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA. 96:(12):1999;6914-6919.
149. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59:(11):1999;2532-2535.
150. Marbeuf-Gueye C., Broxterman H.J., Dubru F., Priebe W., Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol. Pharmacol. 53:(1):1998;141-147.
151. Loe D.W., Almquist K.C., Deeley R.G., Cole S.P. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 271:(16):1996;9675-9682.
152. Renes J., de Vries E.G., Nienhuis E.F., Jansen P.L.M., Müller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 126:(3):1999;681-688.
153. Mao Q., Deeley R.G., Cole S.P. Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. J. Biol. Chem. 275:(44):2000;34166-34172.
154. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:(22):1994;5902-5910.
155. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113:(Pt 11):2000;2011-2021.
156. Chu X.Y., Suzuki H., Ueda K., Kato Y., Akiyama S., Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J. Pharmacol. Exp. Ther. 288:(2):1999;735-741.
157. Zeng H., Bain L.J., Belinsky M.G., Kruh G.D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 59:(23):1999;5964-5967.
158. Zeng H., Liu G., Rea P.A., Kruh G.D. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 60:(17):2000;4779-4784.
159. Gerloff T., Stieger B., Hagenbuch B., Madon J., Landmann L., Roth J., et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273:(16):1998;10046-10050.
160. van der Sandt I.C., Blom-Roosemalen M.C., de Boer A.G., Breimer D.D. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci. 11:(3):2000;207-214.
161. Ushigome F., Takanaga H., Matsuo H., Yanai S., Tsukimori K., Nakano H., et al. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. 408:(1):2000;1-10.
162. Lowes S., Simmons N.L. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 135:(5):2002;1263-1275.
163. Childs S., Yeh R.L., Hui D., Ling V. Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein. Cancer Res. 58:(18):1998;4160-4167.
164. Hendricks C.B., Rowinsky E.K., Grochow L.B., Donehower R.C., Kaufmann S.H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52:(8):1992;2268-2278.
165. Bardelmeijer H.A., Beijnen J.H., Brouwer K.R., Rosing H., Nooijen W.J., Schellens J.H., et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6:(11):2000;4416-4421.
166. Hoki Y., Fujimori A., Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother. Pharmacol. 40:(5):1997;433-438.
167. Smith A.J., van Helvoort A., van Meer G., Szabo K., Welker E., Szakacs G., et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. 275:(31):2000;23530-23539.
168. Jung D., Fried M., Kullak-Ublick G.A. Human apical sodium-dependent bile salt transporter (SLC10A2) gene is regulated by the peroxisome proliferator-activated receptor alpha. J. Biol. Chem. 277:(34):2002;30559-30566.
169. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M. et al., Regulation of multidrug resistance-associated protein 2 (MRP2;ABCC2) by the nuclear receptors PXR, FXR, and CAR. J. Biol. Chem. 277:(4):2001;2908-2915.
170. Guo G.L., Staudinger J., Ogura K., Klaassen C.D. Induction of rat organic anion transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with pregnane X receptor. Mol. Pharmacol. 61:(4):2002;832-839.
171. Loudig O., Babichuk C., White J., Abu-Abed S., Mueller C., Petkovich M. Cytochrome P450RAI(CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism. Mol. Endocrinol. 14:(9):2000;1483-1497.
172. Li D., Zimmerman T.L., Thevananther S., Lee H.Y., Kurie J.M., Karpen S.J. Interleukin-1beta mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent. J. Biol. Chem. 277:(35):2002;31416-31422.
173. Takada T., Suzuki H., Sugiyama Y. Characterization of 5′-flanking region of human MRP3. Biochem. Biophys. Res. Commun. 270:(3):2000;728-732.
174. Lecureur V., Thottassery J.V., Sun D., Schuetz E.G., Lahti J., Zambetti G.P., et al. Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo. Oncogene. 20:(3):2001;303-313.
175. Yu L., Wu Q., Yang C.P., Horwitz S.B. Coordination of transcription factors, NF-Y and C/EBP beta, in the regulation of the mdr1b promoter. Cell. Growth Differ. 6:(12):1995;1505-1512.
176. Sullivan G.F., Yang J.M., Vassil A., Yang J., Bash-Babula J., Hait W.N. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J. Clin. Invest. 105:(9):2000;1261-1267.
177. Sampath J., Sun D., Kidd V.J., Grenet J., Gandhi A., Shapiro L.H., et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J. Biol. Chem. 276:(42):2001;39359-39367.